As the popularity of drugs like Ozempic and Mounjaro soar, researchers, doctors, biotechs, and diagnostic firms see a role ...

In a first-of-its-kind trial, physicians will review neurofilament test results with patients and decide whether to continue ...

The company said it expects to seek regulatory permission to begin clinical testing of VY1706 in the US and Canada in 2026.

NEW YORK – Ratio Therapeutics said this week that it is out-licensing its somatostatin receptor 2 (SSTR2)-targeted radiopharmaceutical discovery capabilities to Novartis. Novartis is paying Ratio $745 ...

Breast cancer patients in England and Wales will not have access to the drug after pricing negotiations failed between NICE and drugmakers.

The firms will initially develop a tool to identify NSCLC patients with EGFR mutations who can benefit from targeted therapy.

The firm is paying €7 million to add fibroblast activation protein-targeting assets to its pipeline, which it will initially develop for bladder cancer.

The company expects the trial to support the submission of a biologics license application with the US Food and Drug Administration in 2026.

In the trial, researchers will test how well Medera's SRD-001 gene therapy improves symptoms in heart failure patients with reduced ejection fraction.

NEW YORK – Apeiron Therapeutics on Tuesday said it enrolled the first patient with MTAP-deleted advanced cancer in a Phase Ia/b trial testing the activity of its PRMT5 inhibitor GTA182. In the ...

The firm is now inking revenue-generating contracts with other biotech companies for its drug response prediction and gene expression analysis capabilities.

If approved by the EC, Tagrisso will be the first targeted therapy for European patients with unresectable EGFR-mutated cancer.